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It is not clear to what extent associations between schizophrenia, cannabis use and cigarette use are due 29 
to a shared genetic etiology. We therefore examined whether schizophrenia genetic risk associates with 30 
longitudinal patterns of cigarette and cannabis use in adolescence, and mediating pathways for any 31 
association to inform potential reduction strategies.  32 
Methods 33 
Associations between schizophrenia polygenic scores and longitudinal latent classes of cigarette and 34 
cannabis use from ages 14 years to 19 years were investigated in up to 3925 individuals in the Avon 35 
Longitudinal Study of Parents and Children. Mediation models were estimated to assess the potential 36 
mediating effects of a range of cognitive, emotional, and behavioral phenotypes. 37 
Results 38 
The schizophrenia polygenic score, based on single nucleotide polymorphisms meeting a training-set p-39 
threshold of 0.05, was associated with late-onset cannabis use (OR=1.23; 95% CI=1.08,1.41), but not with 40 
cigarette or early-onset cannabis classes. This association was not mediated through lower IQ, 41 
victimization, emotional difficulties, antisocial behavior, impulsivity, or poorer social relationships during 42 
childhood. Sensitivity analyses adjusting for genetic liability to cannabis or cigarette use, using polygenic 43 
scores excluding the CHRNA5-A3-B4 gene cluster, or basing scores on a 0.5 training-set p-threshold, 44 
provided results consistent with our main analyses.  45 
Conclusions 46 
Our study provides evidence that genetic risk for schizophrenia is associated with patterns of cannabis 47 
use during adolescence. Investigation of pathways other than the cognitive, emotional, and behavioural 48 
phenotypes examined here is required to identify modifiable targets to reduce the public health burden 49 
of cannabis use in the population. 50 
 51 
 52 
Keywords: ALSPAC, polygenic score, cigarette-use, cannabis-use, schizophrenia, mediation 53 
 54 




Schizophrenia is a highly heritable, severe psychiatric disease with typical symptoms including positive 57 
symptoms such as hallucinations, delusions and thought disorder, negative symptoms such as apathy 58 
and avolition, and cognitive dysfunction. Genome-wide association studies (GWAS) provide strong 59 
evidence of multiple independent loci contributing to the etiology of schizophrenia (Pardiñas et al., 60 
2018; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). However, whilst 61 
individual loci have small effects on risk, multi-locus approaches show that cumulatively, even 62 
moderately associated alleles explain at least a third of schizophrenia genetic risk (Purcell et al., 2009; 63 
Ripke et al., 2013). Based on these alleles, an individual’s genetic liability can be quantified using a 64 
polygenic score, a valuable tool when investigating shared genetics between disorders and how genetic 65 
risk is manifest throughout the life course (Hubbard et al., 2016; Jones et al., 2016).  66 
Cannabis use is more common in individuals with schizophrenia than in the general population (Green, 67 
Young, & Kavanagh, 2005), and a large body of evidence from observational (Moore et al., 2007) and 68 
experimental (D'Souza et al., 2004) studies support a causal effect of cannabis use on psychosis. 69 
However, some recent studies (Carey et al., 2016; Power et al., 2014; Reginsson et al., 2017; Verweij et 70 
al., 2017), though not all (Guloksuz et al., 2019), have found that genetic liability to schizophrenia (as 71 
captured by polygenic scores) is associated with cannabis use, suggesting that the association between 72 
cannabis and schizophrenia might be partly genetically confounded, or represent a pathway from 73 
schizophrenia risk to cannabis use. The latter may result from early manifestations of schizophrenia 74 
liability that may increase an individual’s likelihood to start using cannabis, for example, experiencing 75 
difficulties with peers (Cannon et al., 2001; Malmberg, Lewis, David, & Allebeck, 1998). If a bi-directional 76 
relationship does exist, then identifying the mechanisms by which schizophrenia genetic risk increases 77 
risk of cannabis use could provide important insights about targets to prevent cannabis use in the 78 
population, and particularly in those at genetically high risk for schizophrenia where cannabis reduction 79 
is likely to lead to the greatest benefit in reducing population levels of schizophrenia. 80 
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Schizophrenia is also associated with a higher prevalence of tobacco smoking behaviors compared with 81 
the general population (de Leon & Diaz, 2005; Dickerson et al., 2013). As such, the possibility that 82 
cigarette smoking might increase risk for schizophrenia has gained attention (Gurillo, Jauhar, Murray, & 83 
MacCabe, 2015), although recent work shows that evidence consistent with causal effects on psychotic 84 
experiences are much stronger for cannabis use than they are for tobacco use (Jones et al., 2018). 85 
Schizophrenia polygenic risk, and a schizophrenia GWAS hit in the CHRNA5-A3-B4 gene cluster, are 86 
associated with cigarette smoking phenotypes, including initiation, dependence and heaviness 87 
(Reginsson et al., 2017; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) 88 
which, similar to the findings for cannabis use, raises questions regarding a shared genetic etiology and 89 
direction of effect between cigarette use and schizophrenia, and the potential to gain insights into 90 
mechanisms leading to cigarette use in the population.  91 
We identified, a priori to any analyses, a number of potentially modifiable pathways through which 92 
genetic risk for schizophrenia could theoretically lead to adolescent substance use. Based on evidence of 93 
association with both genetic/familial risk for schizophrenia, and with substance use, these included 94 
peer-victimization, poorer social relationships, deficits in cognitive ability and impulsivity, and emotional 95 
or behavioral problems during childhood (Courtney, Mejia, & Jacobus, 2017; Varese et al., 2012; 96 
Welham, Isohanni, Jones, & McGrath, 2009).  97 
Whilst understanding whether genetic risk for schizophrenia is associated with specific patterns of 98 
substance use, and the pathways involved in these relationships, could provide important insights into 99 
the etiology of both schizophrenia and substance use disorders, disentangling such associations may be 100 
hindered by measurement error in the outcomes, the high correlation between cigarette and cannabis 101 
use that makes it difficult to study independent effects of these substances, and by experimental and 102 
fluctuating use over time which are difficult to capture with single time-point assessments. To overcome 103 
some of these difficulties, we previously used longitudinal latent class analysis (LLCA) of repeated 104 
measurements of adolescent cigarette and cannabis use to identify subgroups of individuals based on 105 
their use or co-use of cigarettes and cannabis and capture information on persistent use as opposed to 106 
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brief experimentation with these substances (Jones et al., 2018). The current study therefore aims to 107 
use these latent classes to: i) examine whether schizophrenia genetic risk is associated with patterns of 108 
cigarette and cannabis use in adolescence, and ii) examine whether genetic effects on substance use are 109 




The sample consisted of participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) 114 
(see Supplementary Methods) (Boyd et al., 2013; Fraser et al., 2013). Details of available data are 115 
accessible through a searchable data dictionary and variable search tool 116 
(http://www.bristol.ac.uk/alspac/researchers/data-access/data-dictionary). Ethical approval for the 117 
study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics 118 
Committees (http://www.bristol.ac.uk/alspac/researchers/research-ethics/). Consent for biological 119 
samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the 120 
use of data collected via questionnaires and clinics was obtained from participants following the 121 
recommendations of the ALSPAC Ethics and Law Committee at the time. 122 
Genetic data 123 
Genetic data were acquired using the Illumina HumanHap550 quad genome-wide single nucleotide 124 
polymorphism (SNP) genotyping platform from 9912 participants. Following quality control assessment 125 
and imputation (see Supplementary Methods), genetic data was available for 7977 ALSPAC individuals. 126 
Measures 127 
Polygenic scores 128 
Polygenic scores for schizophrenia were constructed for each ALSPAC individual using data from the 129 
most recent schizophrenia GWAS based on 40 675 cases and 64 643 controls (Pardiñas et al., 2018) as a 130 
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training set. Following quality control (see Supplementary Methods), polygenic scores were calculated 131 
using the PLINK (v1.9) (Chang et al., 2015; Purcell et al., 2007) ‘score’ command following the 132 
methodology described previously (Purcell et al., 2009).   133 
For the primary analysis, scores were constructed using a list of SNPs with a GWAS training set p-value 134 
threshold ≤ 0.05,which optimally captures phenotypic variance in schizophrenia (Schizophrenia Working 135 
Group of the Psychiatric Genomics Consortium, 2014). Scores were weighted by the logarithm of the 136 
odds ratio (OR) for schizophrenia reported by the training set. 137 
For sensitivity analyses, additional polygenic scores were created based on different GWAS training set 138 
p-value thresholds (P ≤ 0.5, 1e-5 and 5e-8 [genome-wide significant]) and after excluding the CHRNA5-A3-139 
B4 nicotinic receptor gene cluster (chromosome 15: 78- 79.5Mb), a loci which is strongly associated with 140 
smoking cigarette quantity and nicotine dependence (Saccone et al., 2009; Tobacco Genetics 141 
Consortium, 2010) and also genome-wide significantly associated with schizophrenia (Pardiñas et al., 142 
2018; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Weighted polygenic 143 
scores were also constructed for cigarette smoking initiation and cannabis use initiation using results 144 
from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) tobacco and alcohol 145 
use GWAS (n = 1 232 091) (Liu et al., 2019) and from a cannabis use GWAS meta-analysis using data 146 
from the International Cannabis Consortium (ICC) and UK Biobank (n = 184 765) (Pasman et al., 2018), 147 
respectively, using SNPs meeting a p-value threshold ≤ 0.5 in the training set GWAS. As ALSPAC was a 148 
part of the GSCAN and ICC GWAS samples (Liu et al., 2019; Stringer et al., 2016), the SNPs and log ORs 149 
used to generate and weight the polygenic scores were from results after removal of ALSPAC and, due 150 
to data permissions, 23andMe from the GWAS meta-analyses. 151 
Repeated measures of cigarette and/or cannabis use 152 
Repeated measures of cigarette and/or cannabis use in ALSPAC were collected from clinic visits and 153 
questionnaires between approximate ages 14 and 19 years. At each time point, individuals were asked 154 
questions relating to their current use and frequency of use (see Supplementary Methods for more 155 
detail). At each time point, data on cigarette and cannabis use were combined into a 3-category nominal 156 
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variable: “Non-users”, “Cigarette-only users” and “Cannabis users (either with or without cigarettes)” as 157 
previously described (Jones et al., 2018). 158 
Potential mediators 159 
Potential mediators were selected on the basis that they are all premorbid antecedents of 160 
schizophrenia, associated with familial risk of schizophrenia, and/or associated with substance use. 161 
These included: IQ (assessed via the Wechsler Intelligence Scale for Children (Wechsler, Golombok, & 162 
Rust, 1992) at age 8 years), victimization (from the Bullying and Friendship Interview Schedule (Wolke, 163 
Woods, Bloomfield, & Karstadt, 2000) at age 8 years), emotional problems (Strengths and Difficulties 164 
Questionnaire [SDQ] (Goodman, 1999) sub-scale score at age 9 years), antisocial behavior (assessed via 165 
a short structured interview at age 10 years), impulsivity (number of incorrect items on the stop signal 166 
task (150ms delay) (Handley, Capon, Beveridge, Dennis, & Evans, 2004) at age 10 years), friendship 167 
quality (based on 5 items from the Cambridge Friendship Questionnaire (Baron-Cohen & Wheelwright, 168 
2003) at age 12 years), and psychotic experiences (Psychosis-Like Symptom Interview [PLIKSi] (Horwood 169 
et al., 2008) at age 12 years). For more information, see Supplementary Methods. 170 
Statistical analysis 171 
Longitudinal latent class analysis 172 
Using the repeated, 3-category nominal variable of cigarette and cannabis use described above, LLCA 173 
was used to derive distinct behavior patterns of cigarette and/or cannabis use as previously described 174 
(Howe et al., 2017; Jones et al., 2018; Taylor et al., 2017) (see Supplementary Methods). Briefly, 175 
Individuals were included in the analysis if they had cigarette and cannabis use data present for 3 or 176 
more time points. Starting with one class, additional classes were added, and each time the model fit 177 
assessed using proportion of individuals in each class, sample size adjusted Bayesian Information 178 
Criterion (SSABIC) and Lo-Mendell-Rubin likelihood ratio test (LMR-LRT). The optimal number of classes 179 
that explained the variation within the data was achieved. LLCA was performed using MPlus version 8 180 
(Muthén & Muthén, 1998-2017). 181 
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Our previous study using the same data found that a 5-class solution adequately describes the combined 182 
cigarette and cannabis use data between ages 14 to 19 years (Jones et al., 2018). The classes were 183 
defined as: non-users, early-onset cigarette-only users, early-onset cannabis users (with or without 184 
cigarette use), late-onset cigarette-only users and late-onset cannabis users (with or without cigarette 185 
use)(Jones et al., 2018). Based on the patterns of class membership across time (see Jones et al., 2018), 186 
early-onset and late-onset substance use are approximately defined as higher probability of use 187 
between approximate ages 14-16 years and higher probability of use between approximate ages 16-19 188 
years, respectively (see Supplementary Figure 1).  189 
Association analyses 190 
Multinomial logistic regression was used to assess whether polygenic scores predicted latent class 191 
membership. Associations were assessed using a manual implementation of the bias-adjusted three-192 
step method in MPlus (see Supplementary Methods and Heron et al. (2015) for more detail). Association 193 
analyses were conducted using individuals who had cigarette and cannabis use data present for 3 or 194 
more time points and genetic data.  195 
To investigate whether associations between schizophrenia polygenic scores and latent class 196 
membership were influenced by genetic overlap between variants associated with both schizophrenia 197 
and cannabis or cigarette use, analyses were also adjusted for the cigarette smoking initiation and 198 
cannabis use initiation polygenic scores. 199 
As it was not possible to incorporate information on frequency of substance use in our 5-class latent 200 
class approach as this resulted in an unstable model (Jones et al., 2018), we examined whether 201 
schizophrenia polygenic scores were associated with frequency of cannabis or cigarette use using data 202 
from single time-points. To aid future meta-analyses, the association between schizophrenia polygenic 203 
scores and cannabis and cigarette ever versus never use were also investigated. The association 204 
between schizophrenia polygenic scores and ever/never use and frequency of use were assessed using 205 
logistic regression and ordered logistic regression, respectively, in Stata statistical software (version 15; 206 
StataCorp LLC). 207 
9 
 
Mediation analysis 208 
Mediation models were used to assess the direct effects of polygenic risk for schizophrenia on latent 209 
class membership and indirectly through each potential mediator. Mediation models were run in MPlus 210 
using a maximum likelihood estimator, and standard errors for indirect effects were calculated using a 211 
non-parametric bootstrapping approach with 100 replications. As two of the mediators were 212 
dichotomous measures, a counterfactual approach was implemented to allow for incorporation of the 213 
dichotomous mediators with effect estimates that are easily interpretable (Valeri & VanderWeele, 214 
2013). However, it is noted that for the models incorporating continuous mediators, this approach 215 
simplifies to product of coefficient strategy as we did not allow for an interaction between exposure and 216 
mediator.  217 
Class reparameterization  218 
As the main analyses were performed using multinomial logistic regression, the effect estimates are 219 
interpreted as the strength of association between the exposure and each outcome class in relation to a 220 
reference class, rather than the effect of the exposure on class membership in the whole population. To 221 
address whether this influenced our results, we repeated all analyses after reparametrizing the 222 
longitudinal latent classes (maintaining uncertainty in class membership) to examine, primarily, the 223 
effects for late-onset cannabis use as compared to all other classes combined in a logistic regression. 224 
Effects from these analyses therefore represent odds for membership in late-onset cannabis use class 225 
compared to membership in any other latent class.  226 
 227 
Results 228 
There was strong evidence that genetic risk for schizophrenia differed across the combined cigarette use 229 
and cannabis use latent classes (omnibus p = 0.004; Table 1). The schizophrenia polygenic score based 230 
on SNPs meeting a training sample p-threshold of 0.05 was associated with late-onset cannabis use as 231 
compared to non-use (OR = 1.23; 95% CI = 1.08, 1.41). There was also weak evidence of association with 232 
10 
 
decreased odds of late-onset cigarette-only use (OR = 0.87; 95% CI = 0.76, 1.00) as compared to non-233 
use, but little evidence of association with increased odds of early-onset cigarette-only use (OR = 1.13; 234 
95% CI = 0.94, 1.36) or early-onset cannabis use (OR = 1.08; 95% CI = 0.87, 1.33). These associations 235 
persisted after adjusting for cigarette smoking initiation and cannabis use initiation polygenic scores 236 
(Table 1) which both showed evidence of association with the cigarette use and cannabis use latent 237 
classes (omnibus p < 0.001; Supplementary Table 1).  238 
Results were similar when excluding the CHRNA5-A3-B4 gene cluster, and when using a more relaxed p-239 
value threshold for inclusion of SNPs into the schizophrenia polygenic score (p-value threshold ≤ 0.5). 240 
However, evidence was weaker when using polygenic scores based on more stringent p-value 241 
thresholds (p ≤ 1e-5 or p ≤ 5e-8) for SNP inclusion, that capture very little variance in liability to 242 
schizophrenia (Supplementary Tables 2 and 3). 243 
Results were also similar following reparameterization of classes with evidence of an increased genetic 244 
liability for schizophrenia (p-value threshold ≤ 0.05) being associated with a 1.2-fold increase in odds 245 
(95% CI = 1.05, 1.37) of late-onset cannabis use as compared to all other classes combined 246 
(Supplementary Table 4). 247 
Evidence of association between the schizophrenia polygenic score and ever/never substance use as 248 
well as frequency of substance use was generally stronger for cannabis use than for cigarette use, and 249 
also stronger for measures of frequency of use in late adolescence and early adulthood than for 250 
measures of use in early adolescence (Supplementary Tables 5 and 6). 251 
There was weak evidence that genetic risk for schizophrenia was associated with lower quality of 252 
friendships (higher score indicates a lower friendship quality) (Beta = 0.06; 95% CI = -0.01, 0.13), and 253 
lower IQ score in childhood (Beta = -0.05; 95% CI = -0.07, -0.02), but less so with  emotional symptoms, 254 
victimization, antisocial behavior or impulsivity (Supplementary Figures 2 and 3). There was evidence 255 
that higher IQ and engagement in antisocial behavior were associated with an increased odds of late-256 
onset cannabis use (IQ: OR = 1.39; 95% CI = 1.18, 1.64; antisocial behavior: OR = 1.62; 95% CI = 1.02, 257 
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2.56). There was weaker evidence that a higher emotional symptoms score was associated with a 258 
reduction in late-onset cannabis use (OR = 0.91; 95% CI = 0.82, 1.01) (Supplementary Figure 2).  259 
In the mediation analysis, there was weak evidence that the effect of schizophrenia polygenic score on 260 
IQ score at age 8 years acts to reduce the effect of schizophrenia genetic risk on late-onset cannabis use 261 
(indirect effect through IQ at age 8 years: OR = 0.99; 95% CI = 0.97, 1.00), but little evidence that any 262 
other mediators affected this pathway (Table 2). Results were also similar following reparameterization 263 
of classes (Supplementary Table 7). 264 
 265 
Discussion 266 
We examined whether genetic risk for schizophrenia was associated with cigarette and cannabis use 267 
during adolescence within a general population cohort and, where appropriate, tested for mediating 268 
effects of a range of factors measured prior to our outcome measures. Our primary outcome measures 269 
were latent classes summarizing the use of cigarettes and cannabis between ages 14 and 19 years. As 270 
previously reported (Jones et al., 2018), our data was best summarized by 5 classes comprising 271 
individuals with early-onset cigarette-only use, late-onset cigarette-only use, early-onset cannabis use, 272 
late-onset cannabis use, and no use of either substance. In our primary analysis, using a training sample 273 
p-threshold of 0.05 that optimally captures variance in schizophrenia liability, we found that 274 
schizophrenia polygenic risk was most strongly associated with late-onset cannabis use. Early-onset 275 
cigarette and cannabis use class estimates were compatible with the late-onset cannabis use estimate. 276 
However, these estimates were less precise as the classes were substantially smaller and therefore 277 
analyses had lower power. Interestingly, we found that schizophrenia polygenic risk was also associated 278 
with a decreased odds of late-onset cigarette only use, however, this weak association did not survive 279 
after class reparameterization. 280 
Our findings are consistent with other studies showing that schizophrenia polygenic risk is associated 281 
with cannabis use (Carey et al., 2016; Power et al., 2014; Reginsson et al., 2017; Verweij et al., 2017). 282 
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Furthermore, results from both our primary results and sensitivity analyses provide evidence that 283 
genetic risk of schizophrenia is more strongly associated with cannabis use than with cigarette use.  284 
One interpretation of our findings is that genetic risk for schizophrenia confers a risk of substance use 285 
that is more specific for some drug classes than others, perhaps due to pleiotropic effects on more 286 
substance-specific biological pathways than ones that are common across addictive behaviors. However, 287 
as almost all individuals within the cannabis use class also use tobacco this class could just index a more 288 
severe phenotype. Therefore, genetic risk for schizophrenia could confer a risk of multiple substance 289 
use, for example through dopaminergic or opioid function that are biological pathways strongly 290 
implicated across all addictive behaviours (Koob & Volkow, 2016). 291 
It is also possible that the association with late-onset cannabis use is not due to pleiotropic effects of 292 
addiction-related biological pathways, but due to behavioral manifestations of schizophrenia genetic risk 293 
leading to adolescent use of cannabis. To explore this possibility we examined if the strongest 294 
association we observed in our primary analysis, between schizophrenia genetic risk and late-onset 295 
cannabis use, was mediated by lower childhood IQ, emotional problems, victimization, engagement in 296 
antisocial behavior, impulsivity or poorer social relationships, all of which are characteristics associated 297 
with increased risk of schizophrenia incidence or cannabis use (Courtney et al., 2017; Varese et al., 2012; 298 
Welham et al., 2009). Our results suggested that little to none of this association was mediated through 299 
these pathways, and indeed that ‘direct’ effects of schizophrenia genetic risk on late-onset cannabis use 300 
may be stronger than first observed. However, this does not exclude the possibility that other variables 301 
that we did not test mediate this relationship. 302 
Whilst the cognitive, emotional, and behavioral characteristics we examined did not mediate the 303 
relationship between schizophrenia genetic risk and cannabis use, identifying mediating phenotypes 304 
expressed in childhood or adolescence is important not just for understanding the mechanisms 305 
underlying addictive behavior, but also to inform potential targets for early intervention to prevent 306 
substance use and harmful consequences of this. The mediators we examined were measured in 307 
childhood, to ensure they occurred prior to substance use, hence minimizing bias in our models. 308 
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However, a potential limitation of this is that our results might not adequately reflect the relationship of 309 
schizophrenia genetic risk with those same characteristics in adolescence, when they might have a more 310 
immediate effect on substance use behavior.  311 
The association we observe here between schizophrenia genetic risk and cannabis use suggests either 312 
that the association between cannabis use and psychosis observed consistently in epidemiological 313 
studies (Gage, Hickman, & Zammit, 2016; Moore et al., 2007) is, at least in part, due to pleiotropy, or 314 
that cannabis has a causal effect on schizophrenia (and therefore risk variants for cannabis use will also 315 
be identified as risk variants for schizophrenia (Gage, Davey Smith, Ware, Flint, & Munafò, 2016) in 316 
adequately-powered GWASs where there would be many more cannabis users among cases than 317 
controls). In fact, despite the finding from this and other studies that schizophrenia genetic risk is 318 
associated with cannabis use, there is little evidence that shared genetic effects confound associations 319 
between cannabis use and risk of psychotic outcomes in epidemiological studies. For example, in a 320 
recent study we found strong evidence that classes of cannabis use were associated with subsequent 321 
risk of psychotic experiences, and that this was not attenuated after adjusting for family history of 322 
schizophrenia (Jones et al., 2018) or schizophrenia genetic risk score (Supplementary Table 8).  323 
One approach that has been used to examine causal effects of cannabis use on schizophrenia and assess 324 
the presence of genetic confounding (horizontal pleiotropy) is Mendelian randomization (MR). Evidence 325 
consistent with a causal effect of schizophrenia risk on likelihood of cannabis initiation, as well as weak 326 
evidence of a causal effect from cannabis initiation to schizophrenia has been reported (Gage, Jones, et 327 
al., 2016; Pasman et al., 2018). Similarly analyses have reported a bidirectional relationship between a 328 
measure of lifetime cigarette smoking (capturing smoking duration, heaviness and cessation) (Wootton 329 
et al., 2018) and schizophrenia risk. However, when there is little understanding of the biological effects 330 
of the genetic instruments used in MR analyses, bidirectional relationships such as these can be difficult 331 
to interpret (Davey Smith & Hemani, 2014), and therefore neither MR studies to date, nor our results 332 
here, lead to substantially stronger conclusions about the causal effects of cannabis and cigarettes on 333 
psychosis than those from more traditional epidemiology designs.  334 
14 
 
Whilst our findings cannot address whether cannabis use has a causal effect on schizophrenia, our 335 
results show that schizophrenia genetic liability does not lead to increased cannabis use through the 336 
mechanisms examined here, and that the investigation of other pathways is required to identify 337 
potentially modifiable targets to reduce the public health burden of cannabis use in the population.  338 
Strengths and limitations 339 
One of the strengths of our study is that we use a large, population-based cohort, with multiple 340 
measures of cigarette and cannabis use data over the whole adolescent period, and thus our results are 341 
much less prone to measurement error than if we had used single time-point measures of substance 342 
use, although it likely still exists to some extent. Furthermore, using a latent class approach with 343 
longitudinal data allows us to maximize use of data for individuals even where participation and 344 
question response has been sporadic, and hence minimize potential selection bias, despite the 345 
considerable levels of attrition over time. We also used the largest, most recent published GWASs of 346 
schizophrenia, cigarette use and cannabis use as training sets for derivation of our polygenic scores. 347 
Nevertheless, there are a number of limitations with our study.  348 
Whilst our use of latent classes derived from information on the combined use of cigarettes and 349 
cannabis use is useful for teasing out independent effects of schizophrenia genetic risk on these 350 
outcomes, it was not possible to define a class of individuals who use cannabis without tobacco, as most 351 
cannabis users smoke cannabis in combination with tobacco (Amos, Wiltshire, Bostock, Haw, & McNeill, 352 
2004), even when they self-report as being cigarette non-smokers (Gage et al., 2014). Furthermore, we 353 
have previously found that a substantial proportion of the people who smoke cigarettes most heavily 354 
also use cannabis (Gage et al., 2014), and thus the cigarette-only class might not include those who have 355 
been most heavily exposed to tobacco. Therefore, we cannot rule out whether the associations 356 
observed between schizophrenia genetic risk and the late-onset cannabis use class is driven by heavier 357 
cigarette use in these individuals than in those within the early-onset cigarette only or late-onset 358 
cigarette only classes (although this would not be consistent with our sensitivity analyses).  359 
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Another limitation is that it was not possible to incorporate information on frequency of substance use 360 
per time point within the combined cannabis and cigarette use model due to model instability. We 361 
therefore also examined frequency of cigarette use and cannabis use using single time-point measures 362 
and found no consistent evidence of association with genetic liability of schizophrenia, with the 363 
exception of increase odds of cannabis use frequency at ages 17 to 19 years. 364 
Furthermore, although we attempted to minimize genetic confounding by adjusting for cigarette and 365 
cannabis initiation polygenic scores, heterogeneity between training set GWAS samples (i.e. differing 366 
ages of participants) and substance use measures (i.e. measures combined experimental and regular 367 
users into a single group) may have reduced their power to detect genetic associations. Furthermore, 368 
polygenic scores for cigarette and cannabis use initiation explain only a small proportion of the variance 369 
for these phenotypes in independent samples. Hence, adjusting for cigarette and cannabis initiation 370 
polygenic scores may have not adequately removed confounding effects resulting from pleiotropy. It is 371 
also possible that our mediation effects are underestimated due to residual confounding. 372 
Finally, as our cohort only included data up to 19 years of age, it was not possible to examine effects of 373 
schizophrenia genetic risk on longer-term patterns, or long-term cumulative use of cannabis or 374 
cigarettes. Addressing these model limitations may become more tractable in the future. 375 
Conclusion 376 
In conclusion, our study provides evidence that genetic risk for schizophrenia is associated with patterns 377 
of cannabis use during adolescence, and that this is not mediated through other measured phenotypic 378 
manifestations of genetic risk for schizophrenia during childhood, including lower IQ, victimization, 379 
increased emotional difficulties, antisocial behavior, impulsivity, or poorer social relationships. Evidence 380 
of association between genetic risk for schizophrenia and cigarette use was weaker. Further studies 381 
need to examine longer-term patterns of use of these substances over time to minimize measurement 382 
error in allocation of substance use classes, and to establish the mechanisms by which these 383 
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Table 1. Associations between polygenic score for schizophrenia and subsequent cigarette and/or 569 
cannabis use as compared to non-use (N = 3925) 570 
P-value threshold for 
inclusion of SNPs into 


















OR (95% CI) 2 OR (95% CI) 2 OR (95% CI) 2 OR (95% CI) 2 P 
Unadjusted 








 (1.08, 1.41) 
0.004 
Adjusted 3 










Note: SNPs, single nucleotide polymorphisms; OR, odds ratio; 95% CI, 95% confidence interval; P, omnibus P-value 571 
for association between polygenic score and cigarette/cannabis use classes 572 
1 Class proportions for latent class membership based on the estimated model 573 
2 Compared to non-use class (class proportion for latent class membership based on the estimated model: 65.3%). 574 
3 Adjusted for polygenic scores for cigarette smoking initiation and cannabis use initiation (PT = 0.5). 575 
  576 
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Table 2. Total effect, direct effect and indirect effect of schizophrenia polygenic score (PT = 0.05) on late-577 
onset cannabis with/without cigarette use as compared to non-use through a range of potential 578 
mediators 579 
Mediator N 
Total Effect Direct Effect 
Indirect Effect via 
mediator 
OR (95% CI) OR (95% CI) OR (95% CI) 
Standardized measure of IQ  
at age 8 years 
3468 1.23 (1.06,1.44) 1.25 (1.07,1.46) 0.99 (0.97,1.00) 
Victimization 
 at age 8 years 
3371 1.22 (1.07,1.38) 1.22 (1.07,1.38) 1.00 (1.00,1.01) 
Emotional symptoms  
at age 9 years 
3522 1.20 (1.04,1.39) 1.20 (1.04,1.39) 1.00 (0.99,1.00) 
Antisocial behavior 
at age 10 years 
3533 1.26 (1.09,1.46) 1.26 (1.09,1.46) 1.00 (1.00,1.01) 
Impulsivity  
at age 10 years 
3344 1.22 (1.06,1.41) 1.22 (1.06,1.41) 1.00 (1.00,1.00) 
Friendship quality  
at age 12 years 
3542 1.27 (1.09,1.48) 1.27 (1.09,1.48) 1.00 (0.99,1.00) 
Psychotic experiences 
at age 12 years 
3572 1.26 (1.12,1.42) 1.26 (1.12,1.42) 1.00 (1.00,1.00) 
Note: OR, odds ratio; 95% CI, 95% confidence interval; PT, p-value threshold for inclusion of SNPs into polygenic 580 
score. Within the mediation models, higher emotional, impulsivity and friendship quality scores indicate more 581 





Supplementary material -- Examining pathways between genetic liability for 




The sample consisted of participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) 
longitudinal birth cohort which recruited 14,541 pregnant women residing in the former Avon Health Authority 
area with an expected delivery date between April 1991 and December 1992. Of the initial 14,541 pregnancies, 
14,062 were live births and 13,988 were alive at 1 year (Boyd et al., 2013, Fraser et al., 2013). When the oldest 
children were approximately 7 years of age, an attempt was made to bolster the initial sample with eligible cases 
who had failed to join the study originally resulting in an additional 913 children being enrolled. The total sample 
size for analyses using any data collected after the age of 7 years is therefore 15,454 pregnancies, resulting in 
15,589 fetuses. Of these 14,901 were alive at 1 year of age. Collection of a range of measures from ALSPAC 
mothers and their children is still ongoing and details of available data are accessible through a fully searchable 
data dictionary and variable search tool (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary). 
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research 
Ethics Committees (http://www.bristol.ac.uk/alspac/researchers/research-ethics/). Consent for biological 
samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of 
data collected via questionnaires and clinics was obtained from participants following the recommendations of 
the ALSPAC Ethics and Law Committee at the time. 
Genetic data 
Avon Longitudinal Study of Parents and Children (ALSPAC) participants genetic data were acquired using the 
Illumina HumanHap550 quad genome-wide single nucleotide polymorphism (SNP) genotyping platform from 
9912 participants. Individuals were excluded from further analysis on the basis of gender mismatches, minimal or 
excessive heterozygosity, disproportionate levels of individual missingness (>3%), evidence of cryptic relatedness 
(>10% of alleles identical by descent), and being of non-European ancestry (assessed by multidimensional scaling 
analysis including HapMap 2 individuals). SNPs with a minor allele frequency (MAF) of < 1%, Impute2 information 
quality metric of < 0.8, a call rate of < 95% or evidence for violations of Hardy-Weinberg equilibrium (p value < 5 x 
10-7) were removed. Imputation of the target data was performed using Impute V2.2.2 against the 1000 genomes 
reference panel (Phase 1, Version 3; all polymorphic SNPs excluding singletons), using 2,186 reference haplotypes 
(including non-Europeans). Following quality control assessment and imputation and restricting to 1 young person 




Polygenic scores for schizophrenia were constructed for each ALSPAC individual using data from the most recent 
schizophrenia GWAS based on 40,675 cases and 64,643 controls (Pardiñas et al., 2018) as a training set. Polygenic 
scores were calculated using the PLINK (v1.9)(Chang et al., 2015, Purcell et al., 2007) ‘score’ command following 
the methodology described by the International Schizophrenia Consortium (ISC) (Purcell et al., 2009). Prior to 
construction of scores, SNPs were removed from the analysis if they had a minor allele frequency less than 0.01, 
an imputation quality less than 0.8 or if there was allelic mismatch between samples. Due to the high linkage 
disequilibrium (LD) within the extended major histocompatibility complex (MHC; chromosome 6: 25-34Mb) only a 
single SNP was included to represent this region. SNPs were pruned for LD using the PLINK ‘clump’ command to 
remove SNPs in LD (r2 > 0.25) with a more significant SNP in the training set. Windows of 500kb were used to 
assess inter-SNP LD for pruning.  
Repeated measures of cigarette and/or cannabis use 
Measures taken at approximate age 14 years, 16 years and 18 years were collected as part of ALSPAC assessment 
clinics using a computerized interview. Measures taken at approximate age 15 years, 17 years and 19 years were 
collected via ALSPAC postal questionnaires. For each time point, individuals were deemed as cigarette users if 
they were current smokers who smoked at least 1-3 in the previous 6 months (age 14 years), who smoked less 
that once a week, weekly or daily (age 15 and 16 years), had smoked less that once a week, weekly or daily in the 
last 30 days (age 16, 18 and 19 years). Individuals were deemed as non-cigarette users if they had never smoked a 
cigarette, if they had only tried cigarettes once or twice (age 15 and 17 years) or if they had not smoked in the last 
6 months (age 14 years) or last 30 days (age 16, 18 and 19 years). For each time point, individuals were deemed 
as cannabis users if they had used or taken cannabis at least 1-3 times in the past 6 months (age 14 years), 
currently take cannabis less than weekly, weekly or daily (age 15, 16 and 17 years) or at least monthly or less in 
the last 12 months (age 18 and 19 years). Individuals were deemed as non-cannabis users if they had never tried 
cannabis, if they had only ever tried cannabis once or twice or if they used to sometimes use or take cannabis but 
had since stopped.  
For generation of longitudinal latent classes, cigarette and cannabis use data were then combined into a 3-
category nominal variable for each time point: “Non-users”, “Cigarette-only users” and “Cannabis users (either 
with or without cigarettes)” as previously described (Jones et al., 2018). 
To assess the associations between polygenic scores for schizophrenia and frequency of cigarette and cannabis 
use, responses to one or more questions at each time point were used to derive two 3-level ordinal variables for 
cigarette use and cannabis use: “Non-user”, “Occasional user” (typically less than once per week) and “Frequent 




Multinomial logistic regression was used to assess whether polygenic scores predicted latent class membership. 
Associations were assessed using a manual implementation of the bias-adjusted three-step method in MPlus (see 
Heron et al. (2015) for more detail and example of code). The latent classes were first derived without the 
presence of the predictor. The resulting logit parameters defining the relationship between modal and latent 
classes were used as constraints allowing odds ratios (ORs) and confidence intervals (CIs) for the associations to 
be calculated without influencing latent class membership. Association analyses were conducted using individuals 
who had cigarette and cannabis use data present for 3 or more time points and genetic data.  
Potential mediators 
A number of potential mediators were examined: IQ at age 8 years (assessed via the Wechsler Intelligence Scale 
for Children (Wechsler et al., 1992); this measure was standardized [mean =0, standard deviation = 1] before use), 
victimization at age 8 years (a dichotomous measure relating to whether individual experienced relational or 
overt victimization, assessed via a modified version of the Bullying and Friendship Interview Schedule (Wolke et 
al., 2000) at age 8 years), Strengths and Difficulties Questionnaire (SDQ) (Goodman, 1999) score at age 9 years 
relating to emotional symptoms (total scores assessed via parental-completed questionnaire when child was age 
9 years with higher score indicating emotional difficulties), antisocial behavior (a dichotomous measure relating 
to whether individual engaged in any antisocial activities, assessed via a short structured interview at age 10 
years), impulsivity (assessed using the number of incorrect stop signal trials at a 150ms delay during the stop 
signal task (Handley et al., 2004) administered at age 10 years with a higher score indicating a higher level of 
impulsivity), friendship quality score (total score based on 5 items from the Cambridge Friendship Questionnaire 
(Baron-Cohen and Wheelwright, 2003) at age 12 years with a higher score indicating worse friendship quality), 
and psychotic experiences (a dichotomous measure relating to whether individual experienced hallucinations 
(visual and auditory), delusions (spied on, persecution, thoughts read, reference, control, grandiosity, other) and 
experiences of thought interference (broadcasting, insertion and withdrawal), assessed via the semi-structured 
Psychosis-Like Symptom Interview (PLIKSi) (Horwood et al., 2008) at age 12 years). 
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Supplementary Table 1. Associations between polygenic score for cigarette smoking initiation and cannabis use 













OR (95% CI) 1 OR (95% CI) 1 OR (95% CI) 1 OR (95% CI) 1 P 






















Note: SNPs, single nucleotide polymorphisms; OR, odds ratio; 95% CI, 95% confidence interval; P, omnibus P-value for 
association between polygenic score and cigarette/cannabis use classes; PT, p-value threshold for inclusion of SNPs into the 
cigarette use and cannabis use polygenic scores. 
1 Compared to all other classes combined. 
 
 
Supplementary Table 2. Associations between polygenic risk score for schizophrenia minus the CHRNA5-






















































Note: OR, odds ratio; 95% CI, 95% confidence interval; P, omnibus P-value for association between polygenic risk score and 
substance use classes; PT, p-value threshold for inclusion of SNPs into the schizophrenia polygenic score. 





Supplementary Table 3. Associations between polygenic score for schizophrenia and cigarette and/or cannabis 












































Note: SNPs, single nucleotide polymorphisms; OR, odds ratio; 95% CI, 95% confidence interval; P, omnibus P-value for 
association between polygenic score and cigarette/cannabis use classes; PT, p-value threshold for inclusion of SNPs into the 
schizophrenia polygenic score. 
1 Compared to non-use class. 
 
 
Supplementary Table 4. Logistic regression associations between polygenic score for schizophrenia and 




































Note: SNPs, single nucleotide polymorphisms; OR, odds ratio; 95% CI, 95% confidence interval; P, omnibus P-value for 
association between polygenic score and cigarette/cannabis use classes; PT, p-value threshold for inclusion of SNPs into the 
schizophrenia polygenic score. 
1 Compared to all other classes combined. 




Supplementary Table 5. Associations between polygenic score for schizophrenia and cannabis and cigarette use 
(ever versus never) at single time-points 
 OR (95% CI) for cigarette ever versus never use 
PT 
14 years  
(N = 4567) 
15 years  
(N = 4150) 
16 years  
(N = 1896) 
17 years  
(N = 3579) 
18 years  
(N = 3043) 
19 years  





















































 OR (95% CI) for cannabis ever versus never use 
PT 
14 years 
 (N = 4551) 
15 years  
(N = 4164) 
16 years  
(N = 3957) 
17 years  
(N = 3580) 
18 years  
(N = 3015) 
19 years  


























































Supplementary Table 6. Associations between polygenic score for schizophrenia and frequency of cannabis and 
cigarette use (non-use, occasional use, frequent use) at single time-points 
 OR (95% CI) for increasing frequency of cigarette use 
PT 
14 years  
(N = 3578) 
15 years  
(N = 3403) 
16 years  
(N = 3400) 
17 years  
(N = 3105) 
18 years  
(N = 2714) 
19 years  





















































 OR (95% CI) for increasing frequency of cannabis use 
PT 
14 years  
(N = 3557) 
15 years  
(N = 3388) 
16 years 
(N = 3373) 
17 years  
(N = 3098) 
18 years  
(N = 2690) 
19 years  



























































Supplementary Table 7. Total effect, direct effect and indirect effect of schizophrenia polygenic score (PT = 0.05) 
on late-onset cannabis with/without cigarette use as compared to all other classes combined (after class 
reparameterization) through a range of potential mediators 
Mediator N 
Total Effect Direct Effect 
Indirect Effect via 
mediator 
OR (95% CI) OR (95% CI) OR (95% CI) 
IQ  

















Emotional symptoms  


























Friendship quality  

















Note: OR, odds ratio; 95% CI, 95% confidence interval; PT, p-value threshold for inclusion of SNPs into polygenic score. Within 
the mediation models, higher emotional, impulsivity and friendship quality scores indicate more emotional problems, a 
higher level of impulsivity and worse friendship quality, respectively. 
 
Supplementary Table 8. Unadjusted and adjusted associations between cigarette and/or cannabis use and 
psychotic experiences at age 18 years (N = 2923) 
 Definite PE (4.48% definite PEs versus 95.52% suspected PEs or none) 
 Unadjusted Adjusted 1 
 OR (95% CI) 2 P OR (95% CI) 2 P 
Early-onset cigarette-only 2.98 (1.14, 7.78) 
<0.001 
2.96 (1.14, 7.69) 
<0.001 
Early-onset cannabis 3.28 (1.35, 7.97) 3.28 (1.35, 7.95) 
Late-onset cigarette-only 0.58 (0.16, 2.05) 0.59 (0.17, 2.06) 
Late-onset cannabis 2.76 (1.49, 5.11) 2.75 (1.48, 5.10) 
Note: PE, psychotic experiences; OR, odds ratio; 95% CI, 95% confidence interval; P, omnibus P value for association between 
cigarette/cannabis use classes and psychotic experiences at age 18 years.  
1 Adjusted for schizophrenia polygenic risk score (PT = 0.05). 





Supplementary Figure 1. Five-class model of cigarette/cannabis use patterns from a sample of 5,300 individuals 
(Jones et al., 2018). The probability axis represents the probability of a class member being a non-user, a 
cigarette-only user or a cannabis with/without cigarette user at each time point. Class proportions are show as 




































































[3] Late-onset cigarette-only users (14.8%)





















Supplementary Figure 2. Total effect, direct effect and indirect effects of schizophrenia polygenic score (PT = 
0.05) on late-onset cannabis with/without cigarette use as compared to non-use through the following 
continuous mediators: a) IQ, b) emotional symptoms, c) impulsivity, and d) friendship quality. Note that higher 
emotional, impulsivity and friendship quality scores indicate more emotional problems, a higher level of 

















Supplementary Figure 3. Total effect, direct effect and indirect effects of schizophrenia polygenic score (PT = 
0.05) on late-onset cannabis with/without cigarette use as compared to non-use through dichotomous 
measures of a) experiencing victimization, b) participating in antisocial behavior, and c) experiencing psychotic 
experiences. 
 
 
